397 related articles for article (PubMed ID: 29559559)
1. Anaplastic Lymphoma Kinase Mutation (
Carneiro BA; Pamarthy S; Shah AN; Sagar V; Unno K; Han H; Yang XJ; Costa RB; Nagy RJ; Lanman RB; Kuzel TM; Ross JS; Gay L; Elvin JA; Ali SM; Cristofanilli M; Chae YK; Giles FJ; Abdulkadir SA
Clin Cancer Res; 2018 Jun; 24(12):2732-2739. PubMed ID: 29559559
[No Abstract] [Full Text] [Related]
2. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract][Full Text] [Related]
3. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.
Reed DR; Hall RD; Gentzler RD; Volodin L; Douvas MG; Portell CA
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e247-e250. PubMed ID: 30992232
[No Abstract] [Full Text] [Related]
5. Alectinib for advanced
Ly AC; Olin JL; Smith MB
Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
[TBL] [Abstract][Full Text] [Related]
6. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
7. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
8. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Morcos PN; Nueesch E; Jaminion F; Guerini E; Hsu JC; Bordogna W; Balas B; Mercier F
Cancer Chemother Pharmacol; 2018 Jul; 82(1):129-138. PubMed ID: 29748847
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
Masuda N; Ohe Y; Gemma A; Kusumoto M; Yamada I; Ishii T; Yamamoto N
Cancer Sci; 2019 Apr; 110(4):1401-1407. PubMed ID: 30776174
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
[TBL] [Abstract][Full Text] [Related]
11. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Makimoto G; Ohashi K; Tomida S; Nishii K; Matsubara T; Kayatani H; Higo H; Ninomiya K; Sato A; Watanabe H; Kano H; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Toyooka S; Takata M; Maeda Y; Kiura K
J Thorac Oncol; 2019 Nov; 14(11):2009-2018. PubMed ID: 31374369
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
13. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
14. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
Shi R; Filho SNM; Li M; Fares A; Weiss J; Pham NA; Ludkovski O; Raghavan V; Li Q; Ravi D; Cabanero M; Moghal N; Leighl NB; Bradbury P; Sacher A; Shepherd FA; Yasufuku K; Tsao MS; Liu G
Lung Cancer; 2020 Aug; 146():78-85. PubMed ID: 32521388
[TBL] [Abstract][Full Text] [Related]
17. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW
J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
19. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
20. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
